PMID- 16208303
OWN - NLM
STAT- MEDLINE
DCOM- 20060404
LR  - 20171116
IS  - 0391-1977 (Print)
IS  - 0391-1977 (Linking)
VI  - 30
IP  - 3
DP  - 2005 Sep
TI  - Insulin resistance syndrome. A review.
PG  - 101-19
AB  - Insulin is a hormone and a growth factor that elicits a myriad variety of 
      metabolic and mitogenic cellular actions. Insulin resistance (IR) could occur 
      with any of the effects of insulin, even though it usually refers to its ability 
      to stimulate glucose uptake in insulin-sensitive peripheral tissues such as fat 
      and muscle. IR as it applies to the glucose-insulin relationship is distinctly 
      different from the clinical concept of an IR syndrome, which applies to a cluster 
      of metabolic disorders (type 2 diabetes mellitus [T2DM], central obesity, 
      dyslipidemia, hypertension, increased prothrombotic and antifibrinolytic factors/ 
      hypercoagulability and a predilection for heart disease). The rising obesity 
      epidemic portends great significance, as it is associated with a high prevalence 
      of IR. We review the etiopathogenesis of IR, the clinical spectrum, and review 
      the clinical data on the management of IR.
FAU - Vasudevan, A R
AU  - Vasudevan AR
AD  - Division of Endocrinology, Department of Medicine, Baylor College of Medicine, 
      Houston, TX 77030, USA.
FAU - Garber, A J
AU  - Garber AJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Minerva Endocrinol
JT  - Minerva endocrinologica
JID - 8406505
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Insulin Resistance
MH  - *Metabolic Syndrome/diagnosis/etiology/metabolism/therapy
RF  - 132
EDAT- 2005/10/07 09:00
MHDA- 2006/04/06 09:00
CRDT- 2005/10/07 09:00
PHST- 2005/10/07 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2005/10/07 09:00 [entrez]
PST - ppublish
SO  - Minerva Endocrinol. 2005 Sep;30(3):101-19.